(attached both photos – evidence TIDREC Dengue & Covid-19).
INFLUENZA.
;%20tidrec@um.edu.my%20%20(2).jpeg)
;%20tidrec@um.edu.my%20%20(1).jpeg)
‘The Potential Antiviral
Shield Against Flu, Dengue & COVID-19’ is an excellent
choice that is finely balanced for public communication and is reasonably
supported by the scientific base from the two studies.
Here is a breakdown of
why it works so well:
1. "Potential": This is the most important word. It is scientifically honest and responsible. It informs the public of a strong, promising capability based on evidence, without making an unproven medical claim (like "cures" or "treats").
.jpeg)
.jpeg)
.jpeg)
.jpeg)
2.
"Antiviral Shield": This is a
powerful and universally understood metaphor.
"Shield"
effectively communicates the concept of protection and defense, which is
exactly what the studies showed defense for cells against viral infection and
replication.
In Malaysia or the UK, using "defence" would be
perfectly appropriate.
If you are targeting a more international or American audience,
"defense" is the standard.
It
aligns with the mechanisms of action found in the research: preventing viral
entry (like a shield blocking an attack) and strengthening the immune response
(bolstering the body's own shields).
.jpeg)
.jpeg)
.jpeg)
.jpeg)
3.
"Flu, Dengue &
COVID-19": This is specific and credible. It
doesn't make a vague "cures all viruses" claim. It directly
references:
·
The two successful studies on Dengue and
COVID-19 provide the solid, reasonable scientific foundation. (concrete
evidence).
·
The inclusion of Influenza (Flu) is
presented as a rational and highly plausible next target based on the same,
proven mechanisms (broad-spectrum antiviral and immunomodulatory activity). (Logical
Extension).
.jpeg)
Physta® may help and act
against influenza, based on the mechanisms demonstrated in the provided
studies.
Scientific Rationale for
Physta®'s Potential Against Influenza
The positive results
against SARS-CoV-2 and Dengue are not just coincidental; they point to
broad-spectrum antiviral mechanisms that are highly relevant to influenza.
Here’s how the documented effects translate to a potential fight against the
flu:
1.
Direct Antiviral Action (Virucidal &
Replication Inhibition):
·
As seen in the studies: Physta®
demonstrated a direct ability to inhibit viral replication, with IC₅₀ values of
36.3 µg/mL for SARS-CoV-2 and between 33-119 µg/mL for different Dengue
serotypes. This means it directly stops the
virus from multiplying inside host cells.
·
Application to Influenza:
Influenza, like SARS-CoV-2 and Dengue, is an RNA virus that must enter host
cells and hijack their machinery to replicate. The active compounds in Physta® particularly glycosaponins and eurycomanone are
known to interfere with viral entry and the synthesis of vital viral proteins.
It is scientifically reasonable to expect that these compounds could disrupt
the replication cycle of the influenza virus in a similar manner.
.jpeg)
.jpeg)
2.
Immune System Modulation
(A Critical "Multi-Pronged" Approach):
·
As
seen in the studies: The Dengue study highlighted that Physta® increases
platelet counts and lymphocytes, which are crucial for a robust immune
response. The COVID-19 study noted its ability to manage inflammation by
suppressing pro-inflammatory cytokines and increasing T-cell levels.
·
Application to Influenza: A severe
influenza infection is often driven by an excessive inflammatory response known
as a "cytokine storm," which damages the lungs. Physta®'s proven
ability to modulate the immune system is critical here. By potentially:
i.
Enhancing T-cell activity to clear the
virus more efficiently.
ii.
Moderating the cytokine storm to reduce
tissue damage and severe symptoms.
iii.
Supporting overall immune cell counts.
This "multi-pronged" approach, as mentioned
in the Dengue conclusion, would be extremely beneficial in managing influenza,
not just by attacking the virus but by supporting the body's own defense and
recovery systems.
3.
High Safety Profile (Selectivity Index -
SI):
·
As seen in the studies: Both studies show
a high Selectivity Index (SI)—30.7 for SARS-CoV-2 and a high CC₅₀ (968.5 µg/mL)
for Dengue. This means Physta® is effective at concentrations that are
non-toxic to human cells.
·
Application to Influenza: A high SI is the
hallmark of a promising therapeutic. It suggests that Physta® has a wide safety
margin, acting against the virus at low doses without harming the patient's
healthy cells. This is a crucial characteristic for any antiviral treatment.
Based on the compelling
evidence from these two studies, it is not mere speculation but a
scientifically-grounded hypothesis that Physta® could be a potent agent against
the Influenza virus.
The mechanisms of action
it employs direct viral replication inhibition and beneficial immune system
modulation are directly applicable to the pathogenesis of influenza.
Therefore, it is highly
promising that Physta® could act accordingly to help eliminate influenza-like
viruses by:
·
Reducing viral load in the body by
directly inhibiting the virus.
·
Alleviating severe symptoms by modulating
the damaging immune response.
·
Supporting overall recovery by enhancing
key immune parameters.
.jpeg){kind=link}